Zobrazeno 1 - 10 of 1 015 578 pro vyhledávání: '"TYROSINE KINASE"'
4
Akademický článek
Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd‐Generation Bruton Tyrosine Kinase Inhibitor‐Based Therapies.
Autor: Lee, Benjamin J.1,2 (AUTHOR) benjaml9@hs.uci.edu, Liu, Jenny1 (AUTHOR), Griffin, Shawn P.1,2 (AUTHOR), Doh, Jean1,2 (AUTHOR), Ciurea, Stefan O.3 (AUTHOR), Kongtim, Piyanuch3 (AUTHOR), Brem, Elizabeth A.3 (AUTHOR)
Publikováno v: Cancer Medicine. Oct2024, Vol. 13 Issue 19, p1-6. 6p.
Zobrazit plný text záznamu
5
Akademický článek
Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis.
Autor: Nunes RAB; Department of Cardiology, Hospital Alemão Oswaldo Cruz, Rua Treze de Maio 1815, 1º subsolo Bloco B, Bela Vista, São Paulo, SP, 01323-020, Brazil. ra.nunes16@gmail.com., Avezum Á; Department of Cardiology, Hospital Alemão Oswaldo Cruz, Rua Treze de Maio 1815, 1º subsolo Bloco B, Bela Vista, São Paulo, SP, 01323-020, Brazil., de Oliveira Marques M; Department of Hematology and Bone Marrow Transplant, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil., Baiocchi OCCG; Department of Hematology and Bone Marrow Transplant, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil., Bachour P; Department of Hematology and Bone Marrow Transplant, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
Publikováno v: Annals of hematology [Ann Hematol] 2024 Nov; Vol. 103 (11), pp. 4613-4620. Date of Electronic Publication: 2024 Aug 17.
Zobrazit plný text záznamu
6
Akademický článek
Ocular Surface Squamous Neoplasia In Situ Secondary to Bruton Tyrosine Kinase Inhibitor Therapy.
Autor: Bloomquist RF; School of Medicine (R.F.B.), University of South Carolina, Columbia, SC; Department of Ophthalmology (M.V.S., D.T.B.), Charlie Norwood Veterans Affairs Medical Center, Augusta, GA; and Department of Ophthalmology (T.E.F.), Medical College of Georgia, Augusta, GA., Sakhalkar MV, Fowler TE, Bloomquist DT
Publikováno v: Eye & contact lens [Eye Contact Lens] 2024 Nov 01; Vol. 50 (11), pp. 498-499. Date of Electronic Publication: 2024 Sep 20.
Zobrazit plný text záznamu
7
Akademický článek
Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia.
Autor: Ghosh N; Atrium Health Levine Cancer Institute, Charlotte, North Carolina, USA., Manzoor BS; AbbVie, Inc., North Chicago, Illinois, USA., Fakhri B; Stanford University, Stanford, California, USA., Emechebe N; AbbVie, Inc., North Chicago, Illinois, USA., Alhasani H; AbbVie, Inc., North Chicago, Illinois, USA., Skarbnik A; Novant Health Cancer Institute, Charlotte, North Carolina, USA., Jawaid D; AbbVie, Inc., North Chicago, Illinois, USA., Shadman M; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Publikováno v: British journal of haematology [Br J Haematol] 2024 Oct; Vol. 205 (4), pp. 1395-1403. Date of Electronic Publication: 2024 Jul 24.
Zobrazit plný text záznamu
8
Akademický článek
Efficacy and safety of tyrosine kinase inhibitors with thoracic radiotherapy for patients with oncogene-mutated non-small cell lung cancer: a meta-analysis.
Autor: Li, Wenxia1 (AUTHOR), Wu, Peiye1 (AUTHOR), Liang, Zhanpeng1 (AUTHOR), Li, Luzhen1 (AUTHOR), Chen, Yunqi1 (AUTHOR), Zhang, Wenjing1 (AUTHOR), Zhang, Huatang1 (AUTHOR), Fang, Cantu1 (AUTHOR) 3568076269@qq.com
Publikováno v: Radiation Oncology. 11/6/2024, Vol. 19 Issue 1, p1-10. 10p.
Zobrazit plný text záznamu
9
Akademický článek
Fenebrutinib, a Bruton's tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways.
Autor: Langlois J; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland., Lange S; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland., Ebeling M; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland., Macnair W; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland., Schmucki R; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland., Li C; Hotchkiss Brain Institute and the Department of Clinical Neurosciences, University of Calgary, 3330 Hospital Dr NW, Calgary, AB, Canada., DeGeer J; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland., Sudharshan TJJ; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland., Yong VW; Hotchkiss Brain Institute and the Department of Clinical Neurosciences, University of Calgary, 3330 Hospital Dr NW, Calgary, AB, Canada., Shen YA; Genentech, Inc., 1 DNA Way, South San Francisco, CA, USA., Harp C; Genentech, Inc., 1 DNA Way, South San Francisco, CA, USA., Collin L; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland., Keaney J; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland. James.Keaney@roche.com.
Publikováno v: Journal of neuroinflammation [J Neuroinflammation] 2024 Oct 27; Vol. 21 (1), pp. 276. Date of Electronic Publication: 2024 Oct 27.
Zobrazit plný text záznamu
10
Akademický článek
Discovery of A-910, a Highly Potent and Orally Bioavailable Dual MerTK/Axl-Selective Tyrosine Kinase Inhibitor.
Autor: Yu Y; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Jang M; Dong-A ST, 21, Geumhwa-ro, 105beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 17073, Korea., Miyashiro J; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Clark RF; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Zhu GD; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Gong J; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Dai Y; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Frey RR; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Penning TD; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Kim H; Dong-A ST, 21, Geumhwa-ro, 105beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 17073, Korea., Lee HK; Dong-A ST, 21, Geumhwa-ro, 105beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 17073, Korea., Kim JK; Dong-A ST, 21, Geumhwa-ro, 105beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 17073, Korea., Ryu KM; Dong-A ST, 21, Geumhwa-ro, 105beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 17073, Korea., Park SJ; Dong-A ST, 21, Geumhwa-ro, 105beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 17073, Korea., Yoon T; Dong-A ST, 21, Geumhwa-ro, 105beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do 17073, Korea., Li T; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Kurnick MD; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Kapecki NJ; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Li L; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Gorman JV; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Montgomery DA; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Manaves V; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Bromberg KD; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Doktor SZ; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Thakur A; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Wang J; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Smith HA; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Buchanan FG; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Ferguson DC; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Torrent M; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Jakob CG; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Qiu W; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Upadhyay AK; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Martin RL; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Lai A; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States., Michaelides MR; Abbvie, Inc, 1 North Waukegan Road, North Chicago, Illinois 60064, United States.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2024 Oct 10; Vol. 67 (19), pp. 17000-17032. Date of Electronic Publication: 2024 Sep 16.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje